Trial Profile
Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 26 Dec 2022
Price :
$35
*
At a glance
- Drugs Asunaprevir (Primary) ; Daclatasvir (Primary)
- Indications Hepatitis C
- Focus Pharmacodynamics
- Acronyms ImmunoDual
- 16 Oct 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Nov 2014 New trial record